MRC1 and breast carcinoma: Further, even if MMR deficiency does not prove that MMR mutation causes breast cancer, the 51% prevalence of the phenotype in breast cancers in carriers would strongly support the clinical feasibility of testing breast cancer tumors in families suspected of segregating an MMR gene mutation, where no colorectal tumors are available for testing.